Quick Answer
Aptose Biosciences Inc. reported Research And Development Expense of $11.34 million for the year ending 2025.
- Aptose Biosciences Inc. showed a decrease of -24.9% in Research And Development Expense from 2024 to 2025.
- This data is from Aptose Biosciences Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 9 years of available data (2017 to 2025), Aptose Biosciences Inc.'s Research And Development Expense has grown by 80.8%.
- Historical annual values: Fiscal year 2025: $11.34 million | Fiscal year 2024: $15.10 million | Fiscal year 2023: $33.27 million | Fiscal year 2022: $24.53 million | Fiscal year 2021: $45.99 million | Fiscal year 2020: $29.29 million | Fiscal year 2019: $16.84 million | Fiscal year 2018: $18.73 million | Fiscal year 2017: $6.27 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: